Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Utah, has announced that its investigational drug, ofirnoflast (HT-6184), has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of Myelodysplastic Syndromes (MDS). As reported by Drugs.com, this designation is a significant milestone for the company and highlights the potential of ofirnoflast to address a critical unmet need in the management of these rare, life-threatening bone marrow disorders.
Myelodysplastic Syndromes are a group of conditions where the bone marrow fails to produce healthy blood cells, often resulting in anemia, increased infection risk, and bleeding problems. MDS can progress to acute myeloid leukemia (AML), complicating treatment and prognosis. The disease mainly affects older adults, and current therapies, such as hypomethylating agents and growth factors, provide limited benefits and do not directly target the root causes of inflammation underlying MDS.
Ofirnoflast is a first-in-class NEK7 allosteric modulator designed to disrupt the formation and promote the disassembly of the NLRP3 inflammasome—an upstream driver of chronic inflammation implicated in a variety of diseases, including MDS. By modulating NEK7, ofirnoflast aims to restore immune balance and improve blood cell production, offering a novel approach that avoids broad immunosuppression.
David Bearss, PhD, CEO of Halia Therapeutics, emphasized the importance of this recognition. “This designation underscores the potential of our approach in Myelodysplastic Syndromes and supports our commitment to developing new treatment options for patients living with MDS,” he stated. The company is optimistic that ofirnoflast’s unique mechanism—addressing the inflammatory drivers rather than just the downstream consequences of MDS—could shift the paradigm in treating these disorders.
The FDA’s Orphan Drug Designation is intended to encourage the development of drugs that target rare diseases affecting fewer than 200,000 people in the U.S. Benefits of this status include tax credits for clinical research, exemption from certain FDA fees, and the potential for seven years of market exclusivity upon drug approval. The program also offers grant support for clinical development.
Ofirnoflast is Halia Therapeutics’ lead investigational molecule and has completed a Phase 2 study in MDS evaluating both safety and blood-related outcomes. It is also being explored in other disease areas, including obesity (in combination with semaglutide) and Alzheimer’s disease, where it targets inflammation and immune dysregulation.
Alan F. List, MD, a member of Halia’s Scientific Advisory Board, noted the innovation behind ofirnoflast’s approach: “Inflammasome biology represents a promising frontier for hematologic innovation. Ofirnoflast’s approach is distinctive in that it seeks to modulate the underlying inflammatory drivers of MDS rather than just its downstream effects.”
With this new FDA designation, Halia Therapeutics is positioned to advance ofirnoflast through further clinical development, offering new hope for patients with MDS and related inflammatory disorders.
